# Radiation Necrosis in Neuro-Oncology: Diagnostic Complexity and Precision Radiotherapy Strategies

## TL;DR

Radiation necrosis is a challenging complication of brain cancer radiotherapy, mimicking tumor recurrence and requiring advanced imaging and personalized treatment strategies.

## Contribution

The paper emphasizes the importance of understanding radiation necrosis as a dynamic process and highlights the potential of connectomics-based planning to reduce its occurrence.

## Key findings

- Radiation necrosis incidence ranges from 3 to 26% depending on tumor type and treatment parameters.
- Advanced imaging techniques like MRI and PET help differentiate radiation necrosis from tumor progression.
- Connectomics-based treatment planning may reduce radiation necrosis by preserving brain networks.

## Abstract

Radiation necrosis (RN) is a delayed complication of cranial radiotherapy and is characterized by progressive tissue injury, inflammation, and vascular compromise. Although advances in stereotactic radiosurgery and fractionated radiotherapy have improved tumor control, RN remains a significant source of morbidity that can mimic tumor recurrence both clinically and on imaging. Relevant mechanisms include endothelial injury, disruption of the blood–brain barrier, and glial-driven edema and necrosis. Diagnosis increasingly relies on advanced MRI modalities and metabolic imaging to differentiate RN from tumor progression, while treatment options include corticosteroids, chemotherapeutics, laser therapy, and, in select cases, surgical resection. Ongoing research emphasizes molecular and connectomic biomarkers to refine diagnosis and personalize management. Understanding RN as a dynamic spectrum of processes rather than a binary entity is essential for optimizing therapeutic decision making in neuro-oncology.

Background: Radiation necrosis (RN) is a delayed and potentially debilitating complication of radiotherapy for central nervous system (CNS) tumors. It presents significant diagnostic and therapeutic challenges due to the variable clinical manifestations and overlap with tumor recurrence. Although advances in radiotherapy have improved tumor control, RN remains incompletely understood and inadequately addressed. This narrative review synthesizes current evidence on RN pathophysiology, risk factors, diagnostic strategies, and management approaches. Methods: A literature search was conducted for English-language literature published between January 1990 and December 2024. Studies were included if they addressed RN incidence, diagnosis, treatment, or novel preventive strategies in CNS tumor populations. Relevant findings were synthesized to produce a narrative review summarizing pathophysiology, diagnostic challenges, and treatment strategies. Results: RN results from radiation-induced neurovascular injury, inflammation, and vessel permeability, with incidence ranging from 3 to 26% depending on tumor type, location, and treatment parameters. Risk is influenced by dose, fractionation, cumulative exposure, re-irradiation, and adjuvant therapies. Advanced modalities such as SRS, HFSRT, brachytherapy, proton therapy, and IORT reduce but do not eliminate RN risk. Diagnosis remains challenging despite advanced MRI and PET techniques, with histopathology as the gold standard. Management includes corticosteroids, bevacizumab, surgery, LITT, and experimental therapies. Connectomics-based planning shows promise in minimizing RN by sparing critical brain networks. Conclusions: RN is a clinically significant and multifactorial complication of CNS radiotherapy. Precision treatment modalities and advanced imaging have improved prevention and detection, but diagnostic uncertainty and recurrence risk persist. Integration of connectomics into treatment planning may offer future promise of a reduction in RN-related morbidity by preserving structural and functional network integrity.